CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM072581
035-os BibID:(cikkazonosító)1017 (scopus)85044643567 (wos)000434978700096
Első szerző:Czompa Attila (gyógyszerész)
Cím:Aged (Black) versus Raw Garlic against Ischemia/Reperfusion-Induced Cardiac Complications / Attila Czompa, Kitti Szoke, Jozsef Prokisch, Alexandra Gyongyosi, Istvan Bak, Gyorgy Balla, Arpad Tosaki, Istvan Lekli
Dátum:2018
ISSN:1661-6596 1422-0067
Megjegyzések:Background: Recent evidence of studies suggests that aged black garlic also has health beneficial effect. The major aim of the present study is to compare the effect of raw and aged black garlic on postischemic cardiac recovery. Methods: Male Sprague Dawley rats were randomly divided into three groups. Animals of the first group were fed with raw garlic, animals of the second group received aged black garlic, while the third group served as vehicle treated control. At the end of the treatment, isolated hearts were undertaken to ischemia/reperfusion. Heart function and infarct size were measured and the level of HO-1 and iNOS were studied. Results: We have found superior postichemic cardiac function and reduced infarct size in both garlic treated groups compared to the drug-free control group, indicating cardioprotective effects. However, no significant differences between the garlic treated groups were observed. Our Western blot analysis revealed that raw garlic enhanced the level of HO-1 before ischemia, while in ischemic samples we found elevated HO-1 expression in both garlic treated groups. The level of iNOS was the same before ischemia in all groups, however, a markedly reduced iNOS level in ischemic/reperfused hearts originated from control and raw garlic treated animals was observed. In samples from aged black garlic treated animals, the level of iNOS was not significantly reduced after ischemia/reperfusion.Conclusion: Taken together our results indicate that not only raw but also aged black garlic also possesses cardioprotective effect.
Tárgyszavak:Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
garlic
ischemia
hemeoxygenase
reperfusion
heart
Megjelenés:International Journal of Molecular Sciences. - 19 : 4 (2018), p. 1-13. -
További szerzők:Szőke Kitti Prokisch József (1966-) (vegyész) Gyöngyösi Alexandra (1990-) (táplálkozástudományi szakember) Bak István (1975-) (vegyész, analitikus, farmakológus) Balla György (1953-) (csecsemő és gyermekgyógyász, neonatológus) Tósaki Árpád (1958-) (kísérletes farmakológus, gyógyszerész) Lekli István (1981-) (gyógyszerész)
Pályázati támogatás:OTKA-PD-111794
OTKA
NKFI-124719
NKFI
TÁMOP 4.2.4. A/2-11-1-2012-0001
TÁMOP
GINOP-2.3.2-15-2016-00043
GINOP
EFOP-3.6.1-16-2016-00022
EFOP
ÚNKP-17-4-III-DE-219
ÚNKP
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

2.

001-es BibID:BIBFORM067980
035-os BibID:(WoS)000398743500147 (Scopus)85016285017
Első szerző:Czompa Attila (gyógyszerész)
Cím:Effects of Momordica charantia (Bitter Melon) on Ischemic Diabetic Myocardium / Czompa Attila, Gyöngyösi Alexandra, Szőke Kitti, Bak István, Csépányi Evelin, David D. Haines, Tósaki Árpád, Lekli István
Dátum:2017
ISSN:1420-3049
Megjegyzések:Objective: A rat model is here used to test a hypothesis that Momordica charantia (Bitter melon (BM)) extract favorably alters processes in cardiovascular tissue and is systemically relevant to the pathophysiology of type 2 diabetes (T2DM) and related cardiovascular disease. Methods: Male Lean and Zucker Obese (ZO) rats were gavage-treated for six weeks with 400 mg/kg body weight bitter melon (BM) extract suspended in mucin?water vehicle, or with vehicle (Control). Animals were segregated into four treatment groups, 10 animals in each group, according to strain (Lean or ZO) and treatment (Control or BM). Following six-week treatment periods, peripheral blood was collected from selected animals, followed by sacrifice, thoracotomy and mounting of isolated working heart setup. Results: Body mass of both Lean and ZO rats was unaffected by treatment, likewise, peripheral blood fasting glucose levels showed no significant treatment-related effects. However, some BM treatment-related improvement was noted in postischemic cardiac functions when Lean, BM-treated animals were compared to vehicle treated Lean control rats. Treatment of Lean, but not ZO, rats significantly reduced the magnitude of infarcted zone in isolated hearts subjected to 30 min of ischemia followed by 2 h of working mode reperfusion. Immunohistochemical demonstration of caspase-3 expression by isolated heart tissues subjected to 30 min of ischemia followed by 2 h of reperfusion, revealed significant correlation between BM treatment and reduced expression of this enzyme in hearts obtained from both Lean and ZO animals. The hierarchy and order of caspase-3 expression from highest to lowest was as follows: ZO rats receiving vehicle > ZO rats receiving BM extract > Lean rats treated receiving vehicle > Lean rats administered BM extract. Outcomes of analyses of peripheral blood content of cardiac-related analytics: with particular relevance to clinical application was a significant elevation in blood of ZO and ZO BM-treated, versus Lean rats of total cholesterol (high density lipoprotein HDL-c + low density lipoprotein LDL-c), with an inferred increase in HDL-c/LDL-c ratio?an outcome associated with decreased risk of atherosclerotic disease. Conclusions: BM extract failed to positively affect T2DM- and cardiovascular-related outcomes at a level suggesting use as a standalone treatment. Nevertheless, the encouraging effects of BM in enhancement of cardiac function, suppression of post-ischemic/reperfused infarct size extent and capacity to modulate serum cholesterol, will likely make it useful as an adjuvant therapy for the management of T2DM and related cardiovascular diseases.
Tárgyszavak:Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Ischemia
diabetes
bitter melon
Megjelenés:Molecules. - 22 : 3 (2017), p. 488. -
További szerzők:Gyöngyösi Alexandra (1990-) (táplálkozástudományi szakember) Szőke Kitti Bak István (1975-) (vegyész, analitikus, farmakológus) Csépányi Evelin (1985-) (gyógyszerész) Haines, David Donald (1981-) (gyógyszerész) Tósaki Árpád (1958-) (kísérletes farmakológus, gyógyszerész) Lekli István (1981-) (gyógyszerész)
Pályázati támogatás:OTKA-104017
OTKA
TÁMOP-4.2.4. A/2-11-1-2012-0001
TÁMOP
GINOP-2.3.2-15-2016-00043
Egyéb
OTKA-PD-111794
Egyéb
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:
Rekordok letöltése1